Introduction
Human immunodeficiency virus (HIV)-1 continues to be a global pandemic of enormous consequence to humanity. At the heart of the virus lies its replication inside cells and the comparatively brief moments, it spends in the intracellular spaces. Against this backdrop we consider a therapeutic approach still unperfected for HIV-1 disease. Gene therapy has shown many potential targets.
The toxicity associated with anti-HIV-1 drugs, together with the appearance of newly resistant strains to current drugs, drives the continued search for novel strategies to fight HIV-1. One aim of gene therapy is to provide a cell an intrinsic advantage that inhibits replication of the
In brief Progress
Vectors based on human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), and feline immunodeficiency virus (FIV) have been developed for delivery of transgenes to T cells and hematopoietic cells. Dominant-negative effectors against HIV-1 expressed as peptides with antiviral effects, truncated or mutated host or viral proteins that inhibit viral machinery have been identified. Intrabodies against viral or viral-related host proteins can be delivered to successfully decrease viral replication. Transcription factors designed to specifically bind the HIV-1 promoter and decrease viral transcription have been assessed. Combinations of RNA-based strategies comprising ribozymes, RNA decoys, and short interfering RNA (siRNA) to efficiently block viral replication are being evaluated. Cells haven been engineered to express gp41-derived peptides on their surface to block HIV-1 entry.
Prospects
Novel vectors based on viral chimeras and/or specific receptor-pseudotypes will be developed. Peptide libraries, expressed within or on the surface of the cell, will be useful as tools for the discovery of small molecules that interfere with the HIV-1 life cycle. Specific targeting of infected HIV-1 cells, based on gp120 expression, can be developed for killing of target cells or gene delivery. The multivesicular body (MVB) machinery and Gag protein might be targeted to inhibit HIV-1 budding. The species-specific human restriction factor Trim5a (Trim5a hu ) can be engineered to increase affinity for HIV-1 capsid; binding to engineered factors will result in efficient destruction of the viral particle. Blocking the antiviral APOBEC3G deaminase/Vif (the virion infectivity factor) interaction will inhibit viral replication. Factors that render a cell nonpermissive to infection, such as Murr1, will be characterized and used as targets in gene therapy regimen. Novel secreted factors will account for CD8+ T cells antiviral activity and be expressed in different cell types to inhibit infectivity.
virus. Perhaps the most exciting information that has become available in recent years has been a further understanding of host processes that HIV-1 exploits to further its own replication. Ongoing research on HIV-1 is continuously uncovering host genes and their protein products that appear to play a role in aspects of the viral life cycle. In most of these cases, HIV-1 proteins depend upon interactions with host proteins. We strongly believe that such novel targets for gene therapy present a unique set of opportunities for further progress against HIV-1. While these targets themselves might not present a valid consideration for gene therapy, gene therapy approaches in animal models, or even in compassionate care experiments in human, might validate them for further consideration when new pharmaceutical approaches become available to target.
Infection with HIV-1 ( Figure 1 ) starts with the recognition of, and binding to, the CD4 receptor and coreceptor (mainly CCR5 or CXCR4) allowing fusion with the cell membrane. Entry then proceeds with the uncoating of the viral particle, releasing the main enzyme reverse transcriptase (RT), the product of the pol gene. RT generates proviral DNA from the viral genome, which is then transported into the nucleus as part of the preintegration complex. In the nucleus, integrase is responsible for the insertion of the proviral DNA into the host chromosome. The provirus can then be silent for long periods of time until the transcriptional machinery of the host cell activates transcription of viral genes leading to viral replication. mRNA copies are transported into the cytosol where translation of polypeptides and protease proceeds. The genomic RNA and structural proteins form a complex, while protease cleaves the polypeptides into their final active form. The viral particle can then undergo assembly and be released from the cell by budding or lysis. As will be assessed in the course of this review, multiple steps in the life cycle are potential targets for intervention. Proof-of-concept experiments will be reviewed that have validated each of these and their relative merit will be discussed.
We will assume for this review that gene transfer of suitable long-term progenitor cells, such as stem cells, will be the basis of a gene therapy approach. That, coupled to appropriate cell-type specific promoters will provide appropriate expression in relevant cells of antiviral or protective genes.
Vectors based on HIV-1, SIV, and FIV have been developed for delivery of transgenes to T cells 3 and discussed below. HIV-1 based vectors have also been shown to have activity against HIV-1 itself. [4] [5] [6] Importantly, HIV-1 vectors especially have shown excellent utility in infecting hematopoietic stem cells. [7] [8] [9] Despite the appeal of certain features of HIV-1-based vectors, non-HIV-1-based lentiviral vectors that are able to infect nondividing cells might have a distinct 'psychological' advantage over HIV-1-based vectors for human gene therapy. Patients are understandably wary of being infected with HIV-based vector even when such vectors are completely safe, and there is no comprehensible possibility of them causing an acquired immunodeficiency syndrome (AIDS)-like syndrome. One such example of a non-HIV-1-based lentiviral vector is derived from the a-pathogenic molecular virus clone SIVagm3mc of the simian immunodeficiency virus (SIV) infecting African green monkeys. This vector, pseudotyped with the vesicular stomatitis virus G-protein (VSV-G), transduced both proliferating and growth-arrested mammalian cell lines, including human lines. The SIVbased vector, pseudotyped with its own envelope (homologous SIV(SIV)) was able to selectively transduce human CD4(+)/CCR5(+) cells. 10 Nonprimate retroviral vectors, like the feline immunodeficiency virus (FIV)-based vectors have also been developed. [11] [12] [13] Importantly, although the virus used in delivery may vary (HIV, SIV, or FIV), the main objective of such approaches is the same. All these viruses are capable of delivery of genetic materials directly into the genome of the cell. This not only allows for the cell to which the gene has been delivered to express the protective gene therapy but also any daughter cells that derive from that cell should also carry the protective vectors. Since a hallmark of HIV-1 is to infect and debilitate the immune system by destroying cells that are expanding to fight infections, this is of course a key consideration in any gene therapy approach. For the purposes of this review, we will assume that gene therapy will be carried out by infection of appropriate target cells (such as hematopoietic stem cells) using vectors that integrate into the target DNA. Other targets could include neural cells that are occasionally believed to be infected with HIV-1, and lentiviral-based vectors have been used to transduce neuronal cells efficiently. Although the vector for delivery is critical, and the target cell type is as important, a major consideration must be the viral-host processes to be inhibited.
Dominant-negative effectors against HIV-1 inhibit viral replication
Dominant-negative effects against HIV-1 have been aimed at interfering with a variety of different processes in the viral life cycle. For instance, studies have been aimed at interfering with the expression of the host cell membrane protein CCR5 (chemokine receptor 5), since CCR5 serves as an important coreceptor for certain subtypes of HIV-1 in the body. Much of the expectation of success in such an approach comes from the fact that individuals homozygous for the 32-bp deletion mutant D32-CCR5 are more resistant to macrophage-tropic (Mtropic) HIV-1 infection than individuals who are wild type for the receptor. In a recent study, the D32-CCR5 construct was fused to the amino-acid motif KDEL (KDEL can drive retention of fused proteins in the endoplasmic reticulum). This construct significantly decreased CCR5 membrane expression by a transdominant negative manner, 14, 15 partially inhibiting HIV-1 Mtropic infection in T cells expressing this construct. Another fusion construct based on an intracellular chemokine or intrakine approach relies on the same D32-CCR5 fused to RANTES, showing significant interference with R5 strain HIV-1 infection and replication in human peripheral blood lymphocytes (PBL). Thus, this suggests that downregulation of the first phase of the viral entry process can successfully prevent viral entry.
Post entry of the cell, the virus offers a number of enticing targets for interfering with its replication. For instance, the multimerization of Vif (the virion infectivity factor) has been shown to be essential in the life cycle of the virus. 16 Vif is absolutely necessary for productive HIV-1 infection of PBL and macrophages. It overcomes the antiviral effects of host factors such as the C-to-U deaminase enzyme APOBEC3G (see below) and facilitates thereby efficient infection of nonpermissive cells. This protein appears to interact with the HIV-1 Gag polyprotein P55Gag; this seems to drive the efficiency of infectivity of progeny virions by modulating assembly, budding, and/or maturation. Disrupting Vif assembly is an attractive target for gene therapy and several published studies 16, 17 are aimed at finding peptides that in a transdominant negative manner disrupt its oligomerization. In one study, a 12-mer containing the aminoacid sequence PXP motif, proline-X-proline, identified through phage display, inhibited Vif oligomerization in vitro. Other peptides, derived from the Vif sequence, had a similar ability to inhibit Vif oligomerization. In particular, a 15-mer containing the amino-acid sequence motif PPLP was found to be significant for inhibiting Vif multimerization. More importantly, these peptides strongly inhibited HIV-1 replication in nonpermissive H9-cells, 17 showing their broad utility. Another example based on oligomerization involves the HIV-1 Vpr protein. Vpr is capable of inducing G2 cell cycle blockade. 18, 19 A mutation at residue 73 in Vpr results in a virus with both lower transcriptional activity and an inability of Vpr to block the cell cycle at G2. This effect is due to heterodimerization between wild-type and mutant proteins, thereby inactivating the complex. 20 Thus, delivery of debilitated viral proteins can interfere with formation of 'normal' viral complexes and could be high on the list of therapies to be considered.
As the viral preintegration complex approaches its 'safe harbor' in the DNA of the cell, an interesting transdominant negative target is the integrase machinery itself. HIV-1 assembles host proteins to facilitate its integration into the genomic DNA. One host protein, termed Integrase interactor 1 (INI1), has been shown to interact with HIV-1 integrase (IN). A fragment of INI1 spanning the minimal integrase-interaction domain (amino acids 183-294) strongly inhibited virion production and replication. The ectopic expression of this Gene therapy approaches for AIDS R Wolkowicz and GP Nolan fragment inhibited HIV-1 replication in a transdominant manner by binding to integrase within the context of Gag-Pol. This interaction possibly interferes with the proper multimerization of Gag and Gag-Pol. 21 As viral proteins are expressed post integration, there are numerous places at which virus assembly offers a choice for disabling virus functions. One promising juncture could be to inhibit the processing of precursor proteins of HIV-1 (akin to protease inhibition, but by a different process). In such experiments, a1-antitrypsin (AT) was delivered into PBL via a simian virus (SV-40) vector. Processing of both gp160 and p55 were reduced. 22 HIV-1 replication may be blocked or decreased by interfering with cellular serine proteases or viral aspartyl proteases. 23 Possibly by targeting multiple aspects of viral postprocessing one might attain a synergistic effect with more standard orally delivered protease inhibitors.
Since the virus co-opts protein processing machinery from the host, these targets must be carefully chosen to minimize side effects on the host cell itself. It is likely, however, that some targets can be found in which the virus takes advantage of a cellular process that is not directly essential to the biology of the cell, but is critical to the virus. Such efficacy-toxicity issues are a standard consideration in pharmacology with small molecules, so this is not a new concept, just a different application of well-understood caveats.
Intrabodies against viral or viral-related host proteins can be delivered to successfully decrease viral replication
The effectiveness of intracellular expression of recombinant antibodies, or intrabodies, in intracellular immunization against HIV-1 is shown in an increasing number of studies. Targeting of Vif may have important repercussions on viral assembly and reverse transcription, as Vif is needed for efficient infectivity, viral replication, and completion of proviral DNA synthesis. Another way to interfere with Vif function is to create and express a Vifspecific single-chain antibody (scFv) in the cytoplasm of T cells. 24 In this study, the intrabody was capable of binding Vif and cells expressing the a-Vif intrabody were more resistant to infection by several strains of HIV-1 than were cells without the intrabody. Moreover, the viral particles produced by intrabody-expressing cells were not able to complete reverse transcription in subsequently infected cells. Finally, peripheral blood mononuclear cells (PBMC) transduced with HIV-1-based vectors carrying the a-Vif intrabody were resistant to laboratory-adapted and primary HIV strains. 24 In another example, retroviral plasmid-based delivery was used to express intrabodies to the a-HIV-1 Gag p17 protein in the cytoplasm of primary human T cells and in Jurkat cells (a human CD4(+) T cell line). 25 When these cells were challenged with several strains of HIV-1, replication was strongly inhibited, although the degree of resistance varied and was not efficient in cells that sustained high viral replication. The inhibition was at post-entry and reverse transcription levels, as only p24 and not proviral DNA differed between the scFvtransduced human primary T cells and control. Several scFv specifically binding to RT have been found 26 that inhibit RT activity in vitro. Naturally, their blocking activity has yet to be confirmed when expressed as intrabodies. Clearly, more genes expressing antiviral epitopes antibody motifs or other intrabodies have yet to be exploited, but should prove an interesting avenue for further study. The biggest drawback of the technique is that the virus would obviously attempt to elaborate mutations in the epitopes recognized by the intrabody to create 'resistance'.
One approach around this hurdle is that intrabodies might be efficient for AIDS gene therapy when targeted not against viral proteins themselves, but against proteins interacting with them. And in this manner, the assumption is that the virus could not readily evolve a manner to dislodge the blocking antibody from its proposed suitor. Potential targets for such an approach are the receptors for the virus, such as the chemokine coreceptor CXCR4, as shown in some studies. An scFv derived from the a-CXCR4 monoclonal antibody 12G5 was delivered into HeLa cells expressing the CD4 main receptor. These cells were able to specifically inhibit replication of T-tropic HIV-1 strains. 27 Another recent example employs intrabodies to target the transcription activation machinery of the virus. ScFv were isolated from a phage display assay for their affinity to the human cyclinT1 subunit (hCyclinT1), one of the components of the positive transcription elongation factor complex (P-TEFb). Tat is known to interact with hCyclinT1 and activate elongation of RNA polymerase II at the HIV-1 long terminal repeat (LTR). In this study, several scFv were able to inhibit HIV-1 replication when expressed as intrabodies in non-Hodgkin's T-cell lymphoma-derived Supt1 cells. 28 The question obviously arises whether such targets are reasonably considered in the context of normal primary cells. Appropriate studies in normal hematopoietic cells in the context of a normal immune system in higher mammals would be warranted prior to any human studies.
Transcription factors to specifically bind the HIV-1 promoter and decrease viral transcription have been assessed
In an elegant set of experiments, intracellular immunity was induced by transcriptional repression. Those experiments take advantage of the zinc-finger DNA-binding domain for the engineering of a transcription repressor of the HIV-1 LTR. The Kruppel-associated box (KRAB) repressor domain from KOX1 has been fused to zincfingers. One of such hybrid proteins is ZFP HIVB-KOX, shown to bind a region overlapping two Sp1 sites within the 5 0 LTR. The protein repressed a Tat-activated 5 0 LTR cellular HIV-reporter assay. HIVBA'-KOX, another protein overlapping the three Sp1 sites present in the promoter efficiently inhibited both basal and Tat-activated transcription in unstimulated and mitogen-stimulated T cells and more importantly, strongly inhibited HXB2 replication. 29 Zinc-finger-based transcription factors were also engineered to bind the HIV-1 promoter at sites both accessible in chromatin structure and highly conserved among the various HIV-1 subgroups. 30 Transient transfection assays showed that KRAB-HLTR3 was able to achieve a 100-fold repression of the HIV-1 promoter. The replication of several HIV-1 strains was reduced in T-cell lines and primary human PBMC when 30 This factor and others could become attractive candidates for intracellular immunization against HIV-1.
Other factors occurring naturally have been shown to efficiently inhibit viral transcription. Such a factor is the RelA-associated inhibitor (RAI) recently identified as a novel inhibitor of nuclear factor kappa B (NF-kB) interacting with the p65 (Rel A) subunit. RAI has been shown to inhibit the DNA binding of Sp1 and consequently the basal HIV-1 promoter activity. 31 Once again, toxic side effects on target cells have to be considered here as there could be effects on other host genes that are deleterious to cell function. Nevertheless, because RAI is not constitutively expressed in susceptible HIV-1 cells, such as CD4 T lymphocytes, macrophages, and microglial cells, its ectopic expression may render them specifically resistant to viral replication. 31 Combinations of RNA-based strategies comprising ribozymes, RNA decoys, and siRNA to efficiently block viral replication are being evaluated RNA-based gene therapy against HIV-1 includes mainly ribozymes, RNA decoys, and siRNAs (Michienzi et al 32 and references therein). Catalytic RNAs also referred to as ribozymes, aimed at disrupting transcription regulation, can be envisioned as an efficient approach for gene therapy. Ribozymes have been engineered to ensure the proper colocalization of ribozyme and target and the high affinity of binding. Catalytic antisense RNA hybrid molecules are composed of ribozymes and stem-loops domains. Such a molecule, composed of the antisense stem-loop of the HIV-1 TAR sequence and a hairpin ribozyme, cleaved TAR-containing RNAs. 33 The same approach was undertaken with hammerhead ribozymes. 34 Artificial RNA substrates containing the TAR-RNA stem-loop were cleaved more efficiently by the hybrid ribozyme-stem-loop antisense domain molecule than the parental hammerhead ribozyme alone. The enhancement is due to the interaction of both complementary stem-loop motifs as deletion of the TAR sequence abolishes the effect. Similar results were obtained with hammerhead-and hairpin-based catalytic antisense RNAs targeted against the HIV-1 LTR, demonstrating that the TAR domain can be used as ribozymetargeting to TAR-containing RNAs. 34 In another study, the envelope-coding region of HIV-1 RNA was targeted at several conserved sites in nine related HIV B-subtype with a multimeric hammerhead ribozyme referred as to Rz1-9. Rz1-9 was shown to inhibit viral replication. 35 Another multimeric ribozyme, Rz10-14, targeted five highly conserved regions in all HIV-1 variants. Rz1-14, a ribozyme that combines Rz1-9 and Rz10-14, was expressed in a human CD4+ T lymphoid cell line. The cells were highly refractory to HIV-1 infection for at least 60 days. The combined version of the multimeric ribozyme was more effective than either Rz1-9 or Rz10-14 alone against all major subtypes of HIV-1. 35 While ribozymes are a promising tool for gene therapy against HIV-1 they may suffer from the same vulnerability as siRNA, that is, the outgrown of HIV-1-resistant mutations as well as limitations in the specificity of the siRNA to a given individual target (and not bystander effects). The sequence-specific mRNA degradation triggered by double-stranded RNA (dsRNA) in animal and plant cells, referred as to RNA interference (RNAi), has become a powerful tool for gene silencing. Short duplexes or siRNAs complementary to a particular mRNA elicit this degradation in human cells. This approach has been applied against early and late steps of HIV-1 replication in human cell lines and primary lymphocytes, targeting both viral and host genes needed for the HIV-1 life cycle. siRNAs against several regions of the HIV-1 genome have been delivered into human cells both as synthetic siRNA duplexes and via plasmidderived expression. HIV-1 RNA was specifically degraded to some extent, impacting HIV-1 infection. 36 Although the siRNA must be optimized for more effective degradation of the HIV target, this study proved the value of RNAi for targeting genomic HIV-1 RNA within the nucleoprotein reverse transcription complex. U6-driven siRNAs targeting HIV significantly inhibited HIV-1 gene expression when cotransfected with provirus. 37 Other studies specifically targeted Rev 38 or Tat and Rev. 39 Although clearly efficient for short-lived inhibition, RNAi might be less efficient in the long run, mainly due to point mutations at HIV-1 target sites, leading to resistance. This indeed occurs as shown in one study targeting the Tat protein with short hairpin RNA (shRNA), where appearance of closely related yet significantly different viral genomes, or quasi-species, was accompanied with point mutation in the Tat region. 40 In a recent study siRNA targeting the Nef gene did confer resistance to HIV-1 replication; nevertheless, HIV-1 variants appear that are immune to interference owing to nucleotide substitutions or deletions within the Nef gene. 41 RNAi should therefore be used in combination with other strategies in order to prevent the appearance of resistant viruses. 41 Other studies have targeted the cellular genes involved in the viral life cycle. In this case, the question is whether silencing of host genes will have detrimental effects on the cells. A recent example addressed this issue with P-TEFb (composed of hCycT1 and CDK9) involved in the transcriptional regulation of many genes other than HIV-1 (through Tat). Both hCycT1 and CDK9 were targeted for gene silencing in HeLa cells. Surprisingly, silencing of P-TEFb was not lethal and inhibited Tat transactivation and HIV-1 replication. 42 In another siRNA experiment, lysyl-tRNA synthetase (LysRS) was chosen as a target. 43, 44 The enzyme is packaged into the virion, apparently via its interaction with Gag, and carries with it the two lysine tRNAs or tRNA Lys isoacceptors tRNA 1, 2 Lys and tRNA 3 Lys . tRNA 3 Lys is used as a primer for reverse transcription. 43 Interestingly, although the overall cellular pool of LysRS was reduced, little or no cellular toxicity was observed. Viruses produced from cells transfected with siRNA showed a reduction in packaging of tRNA Lys , in annealing to viral RNA, and in viral infectivity. 44 This experiment is particularly interesting as it shows that some antiviral candidates, although cellular in nature, may be excellent targets since a reduction in activity might be more detrimental to Gene therapy approaches for AIDS R Wolkowicz and GP Nolan the virus than the cell itself. Other studies include those aimed at targeting the CXCR4 coreceptor, decreasing receptor expression on the cell surface and consequently lowering infectivity by HIV-1 45 or the V3 loop and CD4 binding domains of Env. 46 Some examples target both viral and host genes, for example, Tat and CCR5 (the main coreceptors in macrophage lines). 47 A combination of ribozyme and RNA decoy technologies also seems promising. In one experiment, an anti-CCR5 ribozyme (CCR5RZ) and nucleolar localizing TAR RNA decoy were transduced into cultured and primary cells via lentiviral vectors. A single vector backbone harboring both CCR5RZ and U16TAR decoy transmitted a high degree of resistance against HIV-1 in both primary T cells and CD34(+)-derived monocytes. 48 This strategy has been extended to include siRNA. 49 Ribozymes against CCR5, Tat, rev, and env-coding mRNAs together with RNA decoy targeting rev and siRNA directed against a sequence common to rev and tat mRNAs were transduced into CD34 hematopoietic progenitor cells via retroviral or lentiviral vectors. The cells were differentiated into macrophages in vitro and T cells in vivo in a murine thymopoiesis model. Both transgene-containing macrophages and T cells were phenotypically normal and, importantly, were highly resistant to HIV-1 infection, demonstrating the utility of RNA-based anti-HIV constructs for gene therapy. 49 Cells have been engineered to express gp41-derived peptides on their surface to block HIV-1 entry
The entry process is mediated by both gp120 and gp41 envelope glycoproteins, anchored to the viral surface as trimers through the gp41 transmembrane domain. Upon binding of gp120 to CD4 and coreceptor, the envelope undergoes multiple conformational changes. This results in the gp41 hydrophobic N-terminal fusion peptide insertion into the membrane of the infected cell (Eckert et al 50 and references therein). The T20 peptide that overlaps the C-terminal heptad repeat (HR) of gp41 is an efficient fusion-inhibitor and is now in clinical trials. 51, 52 T20 blocks entry by inhibiting the conformational switch that leads to the six-helix bundle formation comprised of three sets of N-and C-terminal HRs. The T20 peptide, when expressed on the surface of PM-1 cells as an anchored-membrane construct, effectively inhibited HIV-1 entry. 53 A retroviral vector, the peptide itself, and a scaffold for its presentation were optimized for maximal expression and localization on the cell surface. The membrane-anchored C-peptide binds to the free version of gp41 N peptides, suggesting that the membraneanchored C peptides exert their biological effect by binding gp41. 54 Although the appearance of resistant variants might be inevitable, 55 entry inhibitors as those that interfere with fusion carry great hope for anti-HIV therapy.
Prospects
Gene therapy success relies on two prerequisites: firstly, the choice of the right genetic information for transfer and, secondly, efficient transfer of that information into the target cell. Obviously novel approaches for efficient delivery are required. This will include creation of vectors such as viral chimeras and novel pseudotyped vectors based on envelopes that bind to specific receptors expressed on subpopulations of HIV-1-targeted cells. Ways to increase transfer efficiency into hematopoietic progenitors and resting T cells must be developed. Early tries at anti-HIV-1 therapy in neurons has failed due to difficulty in gene transfer efficiency, 23 but this might be overcome in later attempts. Nonretroviral vectors such as Simian foamy virus (SFV-1)-based vectors have been used to transduce several chemically arrested cell lines and terminally differentiated human neurons, 56 and may become a vector of choice.
As we learn more about the life cycle of HIV-1, more protein targets will arise. One fast developing field centers on multivesicular bodies (MVB) or the late endosome, a vesicle biogenesis machinery crucial for virion release. Tsg101, a component of the E vacuolar protein sorting (Vps) machinery 57, 58 is necessary for efficient budding. The p6 product of Gag interacts with Tsg101 through its 'late' domain. Overexpression of the N terminus of Tsg101 strongly inhibited virus production by affecting budding. 59 Expression of the mutant Vps4 ATPase was shown to block HIV-1 formation 60 and disrupted the interaction between AIP1 and CHMP proteins (ESCRT-III), 61, 62 all parts of the MVB machinery. It is possible to envision small molecules or peptides targeted against the p6-Tsg101 interaction or similar pathways. The receptors involved in targeting Gag to the plasma membrane or to the MVB have not yet been discovered, 63 but might become novel targets. Strategies will include expression of peptides that interfere with the MVB machinery specifically needed for viral release or expression of dominant mutants involved in viral assembly for budding.
HIV-1-infected cells express gp120 on their surface. One can envision genetic intervention with HIV-1-infected cells, while noninfected cells are avoided. This could be achieved by pseudotyping a vector with a protein that harbors a peptide with high affinity to gp120. Once this is accomplished, knocking out or introducing a killer enzyme should be straightforward.
In the fast developing field of RNA interference, an increasing number of genes could be targeted for destruction. Lack of effectiveness of siRNA molecules due to high mutational rates can be overcome if degenerative sublibraries of specific target siRNA molecules are used or if targets are highly conserved. RNAbased technologies can be combined with DNA enzymes (Dz's) as another nucleic acid-based approach. Dz's against TAR have shown some protection against HIV-1 in T lymphocytes and human PBMCs. 64 Nucleic acidbased technologies, including aptamers (Joshi et al 65 and references therein) will certainly join forces for AIDS therapy.
One particular area of interest to the authors is the development of intracellularly selected peptide libraries. 66, 67 In such an approach, retrovirally expressed peptides are screened inside cells for those that inhibit certain aspects of viral replication. Once peptides are genetically selected, they are used to 'discover' the host protein or viral process with which they interact and interfere. As such, the peptides are both a means to a gene therapy end as well as a means to discover host cell Gene therapy approaches for AIDS R Wolkowicz and GP Nolan processes on which the virus depends. These host proteins could then be the subject of other antiviral therapies. In our group, we have already used such an approach to derive dozens of peptides that interfere with host cell processes in a variety of fascinating manners. One class of these peptides, interestingly, seems to converge on the inhibition of the COP9 signalosome complex of cells. Different peptides have been independently identified that appear to bind to different members of this multiprotein complex and result in healthy cells, but inhibited HIV-1 replication. Interestingly, some of these peptides interfere with HIV-1 replication, but not MMULV replication. These peptides may be delivered using gene therapy, or may be used as the basis for development of small molecule drugs. Clinical trials with peptides derived from gp41, like T20, 51, 52 are underway. Other peptidic compounds such as the 18-mer T22, the 14-mer T134, and the 9-mers ALX40-4C and CGP 64222 have been identified as CXCR4 antagonists, and as such show anti-T-tropicspecific HIV-1 strain activity. 68 Peptide T, targeting the CCR5 receptor, similarly blocks M-tropic-specific strains. 69 Other studies involved the Vif and protease proteins of HIV-1 that have been shown to interact with each other. 70 A peptide derived from the N-terminus of protease seems to block that interaction and consequently inhibit HIV-1 replication in restrictive cells. 71 It yet has to be seen if these peptides and similar will have antagonistic effects when expressed inside the cell. Obviously, there is room not only for improvement of the inhibitory characteristics of this latter peptide but also for the discovery of other peptides with different targets as well.
Animals already seem to have developed innate inhibitory activities against viral pathogens. For instance, Trim5a from rhesus monkeys (Trim5arh) has been identified as a species-specific restriction factor against HIV-1 in rhesus monkeys. The capsid protein is believed to be the target of the restriction, as Trim5arh seems to interact with capsid and ubiquitinate it for destruction. 72, 73 Human Trim5a (Trim5ahu) could be engineered to increase its affinity for the HIV-1 capsid, or rhesus Trim5a could be expressed in human cells. Other interesting restriction factors include the retroviral innate resistance C-to-U deaminase APOBEC3G involved in the late block of HIV-1 infection. [74] [75] [76] [77] Vif bears two motifs, one that binds APOBEC3G and the second that targets it for proteosomal degradation. 78 Vif blocks APOBEC3G incorporation into nascent virions, but once incorporated does not seem to have any effect on it. 79 Clearly, any molecule that will induce APOBEC3G or block vif interaction would be an attractive target for gene therapy.
The human cellular prion protein (PrP c ) has been shown to have nucleic acid binding and chaperone properties similar to those of nucleo-capsid of HIV-1. 80 Expression of PrP c in 293T cells impaired HIV-1 production at the post-transcriptional level, especially processing of Env and Vpr. 81 By reducing Env incorporation into the virion, PrP c decreased infectivity efficiency of the produced virion. However, using prion-like molecules in a therapy of any sort would come under considerable scrutiny, given the notoriety of the molecule.
The search for factors that convert an infectionpermissive cell into a nonpermissive cell is clearly far from over. In a recent study, Murr1, a protein involved in copper regulation, was implicated in infectivity. HIV-1 efficiently infects quiescent and proliferating CD4+ lymphocytes but does not infect resting T cells. This is due at least in part to Murr1 inhibition of basal and cytokine-stimulated NF-kB activity as shown by the increase in NF-kB activity and decrease in IkBa concentrations upon Murr1 knockdown. 82 By altering the expression of Murr1, one could alter the signaling threshold for effective NF-kB activity 83 and hopefully inhibit HIV-1 infection. A recent report involves the heatshock protein 70 (Hsp70) as a possible novel innate immunity factor against HIV-1. Hsp70 seems to block both G2 and apoptosis in a Vpr-dependent manner, 84 inhibiting the nuclear localization of Vpr. Interestingly, in Vpr-deficient HIV-1-infected macrophages, Hsp70 seems to have an opposite effect on nuclear import and replication. 85 Finally, an important field of study includes a search for immunoregulatory secreted factors that might suppress viral replication without killing the host cell. Such protein or proteins are widely referred to as CD8 antiviral factor or CAF (Devico et al 86 and references therein) and their search is still underway. The secretion of RANTES, MIP-1a and MIP-1b alone cannot account for the CD8+ T cells' antiviral activity. a-Defensins 1, 2, and 3, 87 important in antiviral post reverse transcription activity, were inappropriately believed to be produced by CD8+ T cells 88 and therefore cannot account for CAF. In addition, they have been shown not to be responsible for the Stat1-mediated inhibition of the viral promoter transcriptional activation. 89 Protease activity can also play a role as protease inhibitors such as leupeptin restore HIV-1 infectivity in CD8+ T cells. 90 Other factors, such as ribonucleases may also have antiviral activity. 91 Overall, anti-X4 viruses CAF has yet to be accounted for. The importance of these factors and others to be discovered is clear and it is straightforward to envision how through gene therapy one could endogenously express them in naturally nonproducing cells.
Conclusions
The fight against HIV-1 has hardly begun, and is an evolving dilemma. Classical vaccination approaches appear far off, although studies to boost immune function through vaccination might eventually offer some small hope. However, perhaps the best option still remains to deliver inhibitory genetic blockage to the cells the virus must infect. Of course the solution, as it is in many cases of complex biological phenomena, may rely on a combination of targeted proteins and processes. Inhibitors delivered might be siRNA molecules, dominant negative viral proteins, intracellular antibodies, intrakines, or peptides, or a combination of the above. Inhibitors in the form of small molecules, although less specific and needed in high concentration, might be part of the combination of treatment against HIV-1. We favor the delivery of small peptides (either genetically selected or derived) to interfere dominantly with HIV-1-host cell functions. We believe that such peptides could be delivered as propeptide complexes of multiple peptides that are enzymatically cleaved within cells and then allowed to inhibit their disparate targets.
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Finally, many of the therapies envisioned here and being considered in laboratories around the world are quite expensive. Given the recent issues regarding the cost and access of treating HIV-1 in the developing world, and threats by countries hard-hit, [92] [93] [94] [95] [96] are some of the costly approaches listed above ever going to become standard treatment? How does one make some of the treatments noted herein, if they work, affordable? We believe that the therapies outlined, while not economically viable in the long run, could provide proof-ofprinciple stand-in until pharmaceutical sophistication eventually reaches the specificity of the gene therapy approach. The notion of institutionalizing a network for HIV-1 gene therapy similar to the AIDS Clinical Trial Groups might be a way to determine the best clinical approaches to be undertaken, 97 and point to such proofof-principle targets. Whatever the approaches eventually applied in the clinic, it is becoming obvious that they will rely on the combination of different therapeutic strategies to combat a virus that has taught us as much about the foibles and abilities of our own immune system as any pathogen ever encountered. It will be with some satisfaction, and considerable resolve, that we lay HIV-1 to rest among the great plagues of the past. It is safe to say that gene therapy, to date, has already played a major role in defining the path of that final outcome.
